CombiMatrix Increases Anticipated Net Proceeds from Public Offering to up to $12.2M | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix today raised the expected net proceeds from an intended public offering of its securities.

In a document filed with the US Securities and Exchange Commission, the company said that net proceeds from its proposed offering of 10,000 shares of Series D preferred stock is now estimated at up to $12.2 million, an increase from a previous estimate of up to $10.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.